Vitiligohttps://en.wikipedia.org/wiki/Vitiligo
Vitiligo minangka kondisi kulit jangka panjang sing ditondoi dening bintik-bintik ing kulit sing ilang pigmen. Tambalan kulit sing kena pengaruh dadi putih lan biasane duwe pinggir sing cetha. Rambut saka kulit uga bisa dadi putih. Iku luwih katon ing wong kulit peteng. Faktor risiko kalebu riwayat kulawarga utawa penyakit otoimun liyane, kayata hipertiroidisme, alopecia areata, lan anemia pernisiosa. Iku ora nular. Sacara global kira-kira 1% wong kena vitiligo. Kira-kira setengah nuduhake kelainan sadurunge umur 20 lan paling akeh berkembang sadurunge umur 40.

Ora ana obat sing dikenal kanggo vitiligo. Kanggo sing duwe kulit entheng, tabir surya lan dandanan iku kabeh sing biasane dianjurake. Pilihan perawatan liyane bisa uga kalebu krim steroid utawa fototerapi.

Pengobatan
#Phototherapy
#Excimer laser
#Tacrolimus ointment
☆ Ing asil Stiftung Warentest 2022 saka Jerman, kepuasan konsumen karo ModelDerm mung luwih murah tinimbang konsultasi telemedicine sing dibayar.
  • Non-segmental vitiligo
  • Vitiligo kadhangkala bisa diiringi rambut putih.
  • Vitiligo saka driji luwih angel diobati tinimbang wilayah liyane. Kajaba saka kosmetik sing ora enak, vitiligo iku normal lan ora nular. Ing dermatologi, perawatan sing paling efektif yaiku fototerapi utawa perawatan laser (excimer) 2-3 kali seminggu paling ora 1 taun. Yen sampeyan ora bisa asring menyang rumah sakit amarga alasan finansial utawa amarga sibuk, sampeyan bisa nyoba mesin fototerapi sing disetujoni kanggo panggunaan omah.
  • vitiligo kelopak mata
  • Vitiligo ing tangan
References Vitiligo: A Review 32155629
Vitiligo minangka kelainan kulit umum sing nyebabake bintik-bintik kulit putih amarga ilang melanosit. Riset anyar nuduhake yen iku penyakit otoimun. Sanajan asring katon minangka masalah kosmetik, bisa uga mengaruhi kesejahteraan mental lan urip saben dinane. Ing taun 2011, para ahli nggolongake jinis sing diarani segmental vitiligo kanthi kapisah saka liyane.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
 Advances in vitiligo: Update on therapeutic targets 36119071 
NIH
Pasien vitiligo aktif duwe sawetara pilihan terapi, kayata glukokortikoid sistemik, fototerapi, lan imunosupresan sistemik. Pasien vitiligo sing stabil bisa nemokake relief saka kortikosteroid topikal, inhibitor calcineurin topikal, fototerapi, lan prosedur transplantasi. Kemajuan anyar kanggo ngerteni proses dhasar vitiligo wis nyebabake pangembangan terapi sing ditargetake. Saiki, inhibitor JAK minangka sing paling njanjeni, menehi toleransi sing apik lan asil fungsional, sanajan ana risiko ngaktifake infeksi laten lan efek samping sistemik sing umum karo agen imunosupresif liyane. Panaliten sing terus ditindakake kanggo ngenali sitokin utama sing melu pangembangan vitiligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) . Pamblokiran sitokin kasebut wis nuduhake janji ing model kewan lan sawetara pasien. Kajaba iku, investigasi menyang miRNA-based therapeutics lan adoptive Treg cell therapy lagi ditindakake.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.